Sapient Capital LLC Has $905,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Sapient Capital LLC decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 1.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,906 shares of the medical research company’s stock after selling 43 shares during the quarter. Sapient Capital LLC’s holdings in Amgen were worth $905,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Centricity Wealth Management LLC acquired a new position in shares of Amgen in the 4th quarter valued at $25,000. Pinney & Scofield Inc. acquired a new position in shares of Amgen in the 4th quarter valued at $26,000. Ritter Daniher Financial Advisory LLC DE boosted its position in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 51 shares during the period. Synergy Investment Management LLC acquired a new position in shares of Amgen in the 4th quarter valued at $34,000. Finally, Atala Financial Inc acquired a new position in shares of Amgen in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $297.29 on Friday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market cap of $159.85 billion, a price-to-earnings ratio of 39.38, a P/E/G ratio of 2.63 and a beta of 0.51. The business’s 50-day simple moving average is $281.03 and its 200-day simple moving average is $285.48. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.96 EPS. As a group, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Guggenheim assumed coverage on Amgen in a research note on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 price objective for the company. UBS Group reissued a “neutral” rating and issued a $315.00 price objective (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Erste Group Bank downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Wall Street Zen raised Amgen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 18th. Finally, Johnson Rice set a $294.00 price objective on Amgen in a research note on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $309.22.

Insider Activity

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now directly owns 8,162 shares of the company’s stock, valued at $2,364,368.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.76% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.